Congestive Heart Failure Phase 2 Trial Results Published In Circulation Research
July 14, 2015 19:03 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, July 14, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that Phase 2 trial results of its cell therapy product candidate for the...
Postive Trial Results Of Mesoblast Cell Therapy In Patients With Diabetes And Advanced Chronic Kidney Disease
June 08, 2015 21:12 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, June 8, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that results from the Company's Phase 2 trial in patients with diabetic...
Diabetic Nephropathy Trial Results Selected For Late-Breaking Presentation At American Diabetes Association Annual Meeting
May 18, 2015 05:39 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, May 18, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that Phase 2 trial results of its lead product candidate for the treatment...
Mesoblast Cell Therapy Reduces Inflammation And Reverses Coronary Artery Dysfunction In Rheumatoid Arthritis Preclinical Study
May 12, 2015 05:08 ET
|
Mesoblast
NEW YORK, May 12, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB, USOTC:MBLTY) today announced publication of results in the May issue of the peer-reviewed journal PLOS One showing that its...
Celgene And Mesoblast Enter Into Equity Placement and Right of First Refusal Agreement To Certain Disease Fields
April 12, 2015 20:02 ET
|
Mesoblast
MELBOURNE, Australia and NEW YORK, April 12, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today announced that the Company has entered into an Agreement with US-based Celgene...
Mesoblast Phase 3 Program For Degenerative Disc Disease To Include European Sites After Positive Meeting With European Medicines Agency
April 07, 2015 20:25 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, April 7, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today announced that following positive feedback from its recent meeting with the...
Mesoblast Key Patent Allowed in Japan for the Treatment of Heart Diseases, Stroke, and Other Vascular Conditions
March 26, 2015 23:32 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, March 26, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today announced that the Japanese Patent Office has allowed a key patent covering the...
Mesoblast Selected for Fast Track Access to Potential Investment Incentives in Japan
March 18, 2015 19:32 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, March 18, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that it has been selected by the Japan External Trade Organization...
IMPROVED SURVIVAL IN CHILDREN WITH GRAFT VERSUS HOST DISEASE WHO RESPOND TO MESOBLAST'S CELL THERAPY
February 15, 2015 18:33 ET
|
Mesoblast
NEW YORK CITY and MELBOURNE, Australia, Feb. 15, 2015 (GLOBE NEWSWIRE) -- Results of 160 pediatric patients treated with Mesoblast's proprietary allogeneic Tier 1 product candidate MSC-100-IV for...
Mesoblast Reports 2015 Half-Year Results
February 11, 2015 17:49 ET
|
Mesoblast
NEW YORK CITY, N.Y., Feb. 11, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today provided its 2015 half-year financial results and operational highlights. Mesoblast held cash...